Search results
J&J’s Tremfya superior to Stelara in Phase II/III Chron’s disease trials
Clinical Trials Arena via Yahoo Finance· 3 days agoJohnson and Johnson’s Johnson and Johnson’s Tremfya (guselkumab) was superior to its Stelara...
IBD Stock Of The Day Eli Lilly Breaks Out On Its Way To A Record High
Investor's Business Daily· 3 days agoIn the patients who worsened while taking a prior biologic, 43.4% of mirikizumab patients entered...
Lilly (LLY) Hits Record High on Crohn's Disease Study Data
Zacks via Yahoo Finance· 2 days agoHowever, the results were mixed when the results when the Lilly drug was pitted against J&J’s JNJ...
Finding the Best Psoriasis Treatment: How I Got Psoriasis Relief
Verywell Health via Yahoo News· 3 days agoLiving Life With Psoriasis As with many chronic illnesses, psoriasis cannot be cured, but it can be...
J&J’s Tremfya meets endpoints in Phase III ulcerative colitis trial
Clinical Trials Arena via Yahoo Finance· 3 days agoJ&J’s Tremfya is expected to be the successor to the company’s IL-12/IL-23 inhibitor Stelara...
What to know about biologics for Crohn's disease
Medical News Today· 1 day agoCrohn’s disease biologics are medications created using components of living organisms. Crohn’s disease (CD), along with ulcerative colitis, is one of...
Guselkumab Continues Winning Streak in Crohn's Disease
MedPage Today· 3 days agoInduction and maintenance treatment with guselkumab (Tremfya) demonstrated its safety and efficacy...
Earnings call: Alvotech raises 2024 guidance amid strong biosimilar push By Investing.com
Investing.com· 1 day agoAlvotech, a global biopharmaceutical company, has reported a robust first quarter in 2024, with...
Alvotech (NYSE:ALVO) Releases Quarterly Earnings Results, Misses Estimates By $0.81 EPS
ETF DAILY NEWS· 16 hours agoAlvotech (NYSE:ALVO – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.89) earnings per share for the quarter, missing analysts’ consensus estimates ...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
Morningstar· 4 days agoTeva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk ...